- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02280317
Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)
A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
The study will enrol patients with locally advanced or metastatic prostate cancer. The MTD/MAD may also be evaluated in patients with other advanced tumour types for whom no standard effective therapy is available and a rationale for use of VAL201 exists.
The average timeframe is 18-26 weeks per subject and the outcome measured is a composite average for each group.
Inclusion criteria:
- Specific Inclusion Criteria for Patients with Prostate Cancer
- Patients with incurable, locally advanced or metastatic prostate cancer where a policy of intermittent hormone therapy has been decided. Who have specific clinical parameters.
Specific Inclusion Criteria for Patients with Other Advanced Solid Tumours
- Patients with histologically and/or cytologically confirmed advanced solid tumour for whom no standard effective therapy is available and a rationale for use of VAL201 exists.
Patients with incurable, locally advanced or metastatic prostate cancer where a policy of intermittent hormone therapy has been decided. These patients must also have the following:
- Rising PSA on three samples (once non-castrate levels established); each over 2 weeks apart, with the last two values being greater than 2 ng/mL. Higher than and at least 25% over the nadir.
- Absent or very mild prostate cancer-related symptoms.
- No plans for any therapy for prostate cancer in the next two months.
- General Inclusion Criteria for all Patients
- Adult patients defined by age greater than 18 years at time of consent.
- Ability to give written, informed consent prior to any study-specific Screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.
- Patient is capable of understanding the protocol requirements, is willing and able to comply with the study protocol procedures, and has signed the informed consent document.
- Evaluable disease, either measurable on imaging, or with informative tumour marker(s) and a set of specific biochemical and haematological parameters relating to the specific cancer.
- Negative human chorionic gonadotropin (hCG) test in women of childbearing potential.
- Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control. Female patients may be surgically sterile.
Laboratory values at Screening:
- Absolute neutrophil count ≥1.5 x 109/L.
- Platelets ≥100 x 109/L.
- Haemoglobin ≥9 g/dL without blood transfusion or colony stimulating factor support.
- Total bilirubin <1.5 times the upper limit of normal (ULN);
- AST (SGOT) ≤2.5 times the ULN;
- ALT (SGPT) ≤2.5 times the ULN; ≤5 x ULN for patients with advanced solid tumours with liver metastases.
- Serum creatinine ≤1.5 x ULN or estimated glomerular filtration rate (GFR) of >50 mL/min based on the Cockcroft-Gault formula.
Exclusion criteria
- Specific Exclusion Criteria for Patients with Prostate Cancer Patients has received an anticancer therapy, including investigational agents, within the precious 6 weeks or 4 weeks.
- Any patients who have undergone prior orchidectomy.
- Specific Exclusion Criteria for Patients with Other Advanced Solid Tumours Pregnant or lactating female patients.
- Documented, symptomatic or uncontrolled brain metastases.
- History of clinically significant cardiac condition, including ischemic cardiac event, myocardial infarction or unstable cardiac disease within 3 months previous to the indication of home therapy.
- Known Human Immunodeficiency Virus positivity.
- Active Hepatitis B or C or other active liver disease (other than malignancy).
- Any active, clinically significant, viral, bacterial, or systemic fungal infection within previous 4 weeks prior to home therapy.
- Any medical history that would jeopardize compliance.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Cohort 1: 0.5 mg/kg
VAL201-001 Sub-cutaneous injection.
0.5 mg/kg
|
VAL201-001 Sub-cutaneous injection.
Autres noms:
|
Expérimental: Cohort 2: 1 mg/kg
VAL201-001 Sub-cutaneous injection.
1.0 mg/kg
|
VAL201-001 Sub-cutaneous injection.
Autres noms:
|
Expérimental: Cohort 3: 2 mg/kg
VAL201-001 Sub-cutaneous injection.
2.0 mg/kg
|
VAL201-001 Sub-cutaneous injection.
Autres noms:
|
Expérimental: Cohort 4: 4 mg/kg
VAL201-001 Sub-cutaneous injection.
4.0 mg/kg
|
VAL201-001 Sub-cutaneous injection.
Autres noms:
|
Expérimental: Cohort 5: up to 8 mg/kg
VAL201-001 Sub-cutaneous injection.
8.0 mg/kg; potential to escalate to 16 mg/kg after 3 cycles according to clinician decision Flexibility of dosing enabled under protocol.
|
VAL201-001 Sub-cutaneous injection.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Dose-Limiting Toxicity
Délai: The average timeframe is 18-26 weeks per subject
|
The number of Dose-Limiting Toxicity events is used to determine whether a maximum tolerated dose (MTD) is obtained.
|
The average timeframe is 18-26 weeks per subject
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Pharmacokinetics of VAL201. (Cmax)
Délai: The average timeframe is 18-26 weeks per subject
|
Assessment of pharmacokinetic variables at multiple time points (5 min, 10 min, 15 min, 30 min, 60 min, 90 min, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours after dosing) and multiple dosing days (Cycle 1 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Cycle 6 Day 1) for each patient analysed.
|
The average timeframe is 18-26 weeks per subject
|
Pharmacokinetics of VAL201 (AUC 0-inf)
Délai: The average timeframe is 18-26 weeks per subject
|
Assessment of pharmacokinetic variables at multiple time points (5 min, 10 min, 15 min, 30 min, 60 min, 90 min, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours after dosing) and multiple dosing days (Cycle 1 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Cycle 6 Day 1) for each patient analysed.
|
The average timeframe is 18-26 weeks per subject
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Patients Who Completed 6 Cycles of Treatment
Délai: The average timeframe is 18-26 weeks per subject
|
The number of patients who completed 6 cycles of treatment is compared with the number who withdrew prior to completion of the scheduled 6 cycles
|
The average timeframe is 18-26 weeks per subject
|
Number of Patients Displaying Disease Progression by PCWG2 and/or RECIST Criteria
Délai: The average timeframe is 18-26 weeks per subject
|
Assessment of disease response to treatment by PCWG2 and/or RECIST.
Disease progression is defined by RECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; and by PCWG2 criteria that PSA values did not see an increase of 25% or more and absolute increase of 2 ng/mL or more from the nadir.
|
The average timeframe is 18-26 weeks per subject
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- VAL201-001
- 2013-004009-25 (Numéro EudraCT)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .